"Bupropion" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A unicyclic, aminoketone antidepressant. The mechanism of its therapeutic actions is not well understood, but it does appear to block dopamine uptake. The hydrochloride is available as an aid to smoking cessation treatment.
Descriptor ID |
D016642
|
MeSH Number(s) |
D02.522.818.110
|
Concept/Terms |
Bupropion- Bupropion
- Amfebutamone
- (+-)-1-(3-Chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone
|
Below are MeSH descriptors whose meaning is more general than "Bupropion".
Below are MeSH descriptors whose meaning is more specific than "Bupropion".
This graph shows the total number of publications written about "Bupropion" by people in this website by year, and whether "Bupropion" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 0 | 1 |
1995 | 1 | 0 | 1 |
1998 | 0 | 1 | 1 |
2001 | 1 | 0 | 1 |
2002 | 2 | 0 | 2 |
2005 | 2 | 0 | 2 |
2006 | 1 | 0 | 1 |
2007 | 1 | 0 | 1 |
2008 | 2 | 0 | 2 |
2010 | 3 | 2 | 5 |
2011 | 1 | 0 | 1 |
2012 | 1 | 0 | 1 |
2013 | 1 | 0 | 1 |
2014 | 2 | 0 | 2 |
2015 | 1 | 0 | 1 |
2016 | 2 | 1 | 3 |
2017 | 2 | 0 | 2 |
2019 | 1 | 0 | 1 |
2020 | 1 | 0 | 1 |
2022 | 0 | 3 | 3 |
2023 | 0 | 1 | 1 |
2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Bupropion" by people in Profiles.
-
Deep sequencing of candidate genes identified 14 variants associated with smoking abstinence in an ethnically diverse sample. Sci Rep. 2024 03 16; 14(1):6385.
-
Bayesian regularization to predict neuropsychiatric adverse events in smoking cessation with pharmacotherapy. BMC Med Res Methodol. 2023 04 29; 23(1):107.
-
AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. Gastroenterology. 2022 11; 163(5):1198-1225.
-
The effects of varenicline, bupropion, nicotine patch, and placebo on smoking cessation among smokers with major depression: A randomized clinical trial. Depress Anxiety. 2022 05; 39(5):429-440.
-
Bupropion XL and SR have similar effectiveness and adverse event profiles when used to treat smoking among patients at a comprehensive cancer center. Am J Addict. 2022 05; 31(3):236-241.
-
Initiating Pharmacologic Treatment in Tobacco-Dependent Adults. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2020 07 15; 202(2):e5-e31.
-
Brain Responses to Cigarette-Related and Emotional Images in Smokers During Smoking Cessation: No Effect of Varenicline or Bupropion on the Late Positive Potential. Nicotine Tob Res. 2019 01 04; 21(2):234-240.
-
Pharmacological intervention and abstinence in smokers undergoing cessation treatment: A psychophysiological study. Int J Psychophysiol. 2018 01; 123:25-34.
-
Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial. JAMA. 2017 Jul 11; 318(2):132-145.
-
Benefits of varenicline vs. bupropion for smoking cessation: a Bayesian analysis of the interaction of reward sensitivity and treatment. Psychopharmacology (Berl). 2017 Jun; 234(11):1769-1779.